14 March 2018 - - Tokyo, Japan-based regenerative medical products company SanBio Group (TOKYO: 4592) and Hitachi Chemical Co., Ltd. have reached an agreement through which Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) will manufacture SB623, a proprietary regenerative medicine product under development by SanBio, the companies said.
HCATS is Hitachi Chemical's US subsidiary that engages in contract manufacturing and development of regenerative medicine products.
Under the agreement, late stage clinical products and commercial products of SB623 for the US and Japanese markets will be manufactured using Hitachi Chemical's global facilities.
SanBio is developing and pursuing the rapid commercialization of SB623 in Japan and the US as a new drug candidate for central nervous system disorders.
Hitachi Chemical has established a manufacturing facility in Japan that fulfills a broad range of requirements from manufacture of investigational regenerative medicine agents to that of commercial regenerative medicine products by utilizing the production control systems and manufacturing equipment of the whole Hitachi Group companies.
SanBio, headquartered in Tokyo and Mountain View, California, has cell-based products in various stages of research, development, and clinical trials.
Hitachi Chemical Co., Ltd. (TOKYO: 4217), headquartered in Tokyo, Japan, delivers wide range of products, such as electronic materials, automobile parts, energy storage devices and systems, in global markets.